Silo Pharma IncNASDAQ:SILO
- LAST PRICE1.8500
- TODAY'S CHANGE (%)-0.0301 (-1.6010%)
- Bid / Lots1.7600/ 2
- Ask / Lots1.9600/ 5
- Open / Previous Close1.9200 / 1.8801
- Day Range
- 52 Week Range
- Volume55,867
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SILO |
|---|---|---|
| 09:34 ET | 300 | 1.91 |
| 09:38 ET | 282 | 1.77 |
| 09:39 ET | 299 | 1.84 |
| 09:48 ET | 400 | 1.92 |
| 09:59 ET | 300 | 1.88 |
| 10:42 ET | 600 | 1.9 |
| 10:57 ET | 10000 | 1.91 |
| 11:02 ET | 1071 | 1.8596 |
| 11:04 ET | 250 | 1.8501 |
| 11:09 ET | 100 | 1.895 |
| 11:26 ET | 204 | 1.8605 |
| 11:38 ET | 796 | 1.9 |
| 11:44 ET | 3635 | 1.9 |
| 11:51 ET | 1600 | 1.914 |
| 12:02 ET | 285 | 1.91 |
| 12:21 ET | 300 | 1.91 |
| 12:23 ET | 200 | 1.91 |
| 12:38 ET | 200 | 1.91 |
| 12:41 ET | 200 | 1.91 |
| 12:52 ET | 700 | 1.91 |
| 12:56 ET | 4246 | 1.92 |
| 01:10 ET | 300 | 1.92 |
| 01:12 ET | 615 | 1.92 |
| 01:15 ET | 717 | 1.9274 |
| 01:30 ET | 500 | 1.915 |
| 01:42 ET | 700 | 1.93 |
| 01:50 ET | 250 | 1.91 |
| 02:02 ET | 4600 | 1.93 |
| 02:04 ET | 4219 | 1.9 |
| 02:20 ET | 291 | 1.92 |
| 02:22 ET | 300 | 1.94 |
| 02:40 ET | 100 | 1.9001 |
| 02:42 ET | 300 | 1.9101 |
| 02:45 ET | 300 | 1.94 |
| 02:47 ET | 200 | 1.94 |
| 02:54 ET | 100 | 1.94 |
| 02:56 ET | 5253 | 1.94 |
| 03:30 ET | 300 | 1.9 |
| 03:32 ET | 378 | 1.9 |
| 03:34 ET | 914 | 1.9 |
| 03:36 ET | 298 | 1.89 |
| 03:39 ET | 1600 | 1.865 |
| 03:41 ET | 797 | 1.84 |
| 03:45 ET | 1760 | 1.8854 |
| 03:48 ET | 1000 | 1.865 |
| 03:56 ET | 100 | 1.87 |
| 03:57 ET | 815 | 1.85 |
Apr 23, 2024
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment, from 8:15AM ET on Tuesday Apr 23, 2024 by Dow Jones
8:15AM ET on Tuesday Apr 23, 2024 by Dow Jones
Apr 10, 2024
Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer's Disease Therapeutic, from 8:11AM ET on Wednesday Apr 10, 2024 by Dow Jones
8:11AM ET on Wednesday Apr 10, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Silo Pharma Inc | 5.3M | -1.6x | --- |
ProtoKinetix Inc | 5.4M | -12.1x | --- |
NLS Pharmaceutics AG | 5.2M | -0.3x | --- |
PaxMedica Inc | 5.3M | 0.0x | --- |
Calidi Biotherapeutics Inc | 5.7M | -0.3x | --- |
Avenue Therapeutics Inc | 5.2M | -3.5x | --- |
Company Information
Silo Pharma, Inc. is a developmental stage biopharmaceutical company. The Company is focused on developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It is engaged in acquiring and/or developing intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological disorders. The Company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. Its SP-26 is a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. Its two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS).
Contact Information
- Headquarters
- 677 N. Washington BlvdSARASOTA, FL, United States 34236
- Phone
- 718-400-9031
- Fax
- ---
Executives
- Chairman of the Board, President, Chief Executive Officer
- Eric Weisblum
- Chief Financial Officer
- Daniel Ryweck
- Independent Director
- Wayne Linsley
- Independent Director
- Kevin Munoz
- Independent Director
- Jeff Pavell
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.3M |
|---|---|
Revenue (TTM) | $72.1K |
Shares Outstanding | 2.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.54 |
EPS | $-1.18 |
Book Value | $2.13 |
P/E Ratio | -1.6x |
Price/Sales (TTM) | 74.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -5,346.05% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
